Dr. Ho on How Molecular Subtypes Affect Sequencing

Thai H. Ho, MD, PhD
Published: Friday, Mar 02, 2018



Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses common molecular subtype and phenotype alterations in the epigenetic pathway that are used to predict response to treatment.

Molecular subtypes from the thermogravimetric analysis show that there are certain mutations that are recurrent in renal cell carcinoma; these include VHL, which is the most common mutation, followed by PBRM1, BAP1, and SETD2. Certain types of epigenetic mutations are associated with a favorable response to immune therapy and are currently being studied.

There are also molecular phenotypes that are defined by poor and intermediate risk. These are phenotypes that can be defined based on routine lab work. The patients who were defined as poor and intermediate risk were the patients who were enriched in the CABOSUN study, which led to the approval of cabozantinib. Similarly, these patients were studied in the CheckMate-214 trial, and showed an improved response in combination with nivolumab (Opdivo) and ipilimumab (Yervoy).
 


Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses common molecular subtype and phenotype alterations in the epigenetic pathway that are used to predict response to treatment.

Molecular subtypes from the thermogravimetric analysis show that there are certain mutations that are recurrent in renal cell carcinoma; these include VHL, which is the most common mutation, followed by PBRM1, BAP1, and SETD2. Certain types of epigenetic mutations are associated with a favorable response to immune therapy and are currently being studied.

There are also molecular phenotypes that are defined by poor and intermediate risk. These are phenotypes that can be defined based on routine lab work. The patients who were defined as poor and intermediate risk were the patients who were enriched in the CABOSUN study, which led to the approval of cabozantinib. Similarly, these patients were studied in the CheckMate-214 trial, and showed an improved response in combination with nivolumab (Opdivo) and ipilimumab (Yervoy).
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x